{
    "Trade/Device Name(s)": [
        "SEKURE Acetaminophen L3K Assay"
    ],
    "Submitter Information": "SEKISUI DIAGNOSTICS P.E.I. INC.",
    "510(k) Number": "K180835",
    "Predicate Device Reference 510(k) Number(s)": [
        "K081938"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LDP"
    ],
    "Summary Letter Date": "February 8, 2019",
    "Summary Letter Received Date": "December 26, 2018",
    "Submission Date": "December 21, 2018",
    "Regulation Number(s)": [
        "21 CFR 862.3030"
    ],
    "Regulation Name(s)": [
        "Acetaminophen test system"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "toxicology"
    ],
    "Analyte(s)": [
        "Acetaminophen"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Lithium heparin plasma",
        "Sodium heparin plasma"
    ],
    "Specimen Container(s)": [
        "Serum tube (without gel)",
        "Serum tube with gel in plastic (SST)",
        "Lithium heparin tube with gel in plastic (PST)",
        "Lithium heparin tube without gel",
        "Lithium heparin Barricor tube",
        "Sodium heparin tube without gel"
    ],
    "Instrument(s)/Platform(s)": [
        "Hitachi 717"
    ],
    "Method(s)/Technology(ies)": [
        "Enzymatic assay (Acyl amidohydrolase)",
        "Spectrophotometric (2,5-dimethylphenol chromophore)"
    ],
    "Methodologies": [
        "Enzymatic",
        "Spectrophotometric"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator"
    ],
    "Document Summary": "FDA 510(k) summary for SEKURE Acetaminophen L3K Assay for quantitative measurement of acetaminophen concentration in serum and plasma using enzymatic and spectrophotometric methodology.",
    "Indications for Use Summary": "For the in vitro quantitative measurement of acetaminophen in serum, lithium heparin plasma, and sodium heparin plasma to aid in the diagnosis and treatment of acetaminophen overdose toxicity.",
    "fda_folder": "Toxicology"
}